Clinical Trials on Surgery-Complications in Japan

Total 319 results

Visterra, Inc.

Completed

Safety and Efficacy Study of VIS649 for IgA Nephropathy

Immunoglobulin A Nephropathy | Glomerular Disease | IgAN

United States, Australia, Canada, Hong Kong, India, Japan, Korea, Republic of, Malaysia, Philippines, Singapore, Spain, Sri Lanka, Taiwan, Thailand, United Kingdom
Astellas Pharma Global Development, Inc.
Seagen Inc.

Active, not recruiting

A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)

Bladder Cancer | Urothelial Cancer | Ureteral Cancer

United States, Japan, Korea, Republic of, Taiwan, Argentina, Australia, Austria, Belgium, Canada, Denmark, France, Germany, Italy, Netherlands, Portugal, Russian Federation, Spain, Switzerland, United Kingdom
Novartis Pharmaceuticals

Recruiting

Long-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal Hemoglobinuria

Paroxysmal Nocturnal Hemoglobinuria

United States, Korea, Republic of, Singapore, France, Spain, Taiwan, Italy, Turkey, Germany, Malaysia, Netherlands, United Kingdom, Japan, Lithuania, Czechia, China, Brazil
Merck Sharp & Dohme LLC

Recruiting

A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11)

Melanoma | Renal Cell Carcinoma | Non-Small Cell Lung Cancer

Poland, United States, Argentina, Chile, Japan, Australia, France, New Zealand, South Africa, Turkey
CG Oncology, Inc.

Recruiting

Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin (BOND-003)

Non Muscle Invasive Bladder Cancer | High-grade Ta/ T1 Papillary Disease Bladder Cancer

United States, Korea, Republic of, Taiwan, Japan, Australia
Merck Sharp & Dohme LLC

Recruiting

Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)

Urinary Bladder Neoplasms

United States, Australia, Czechia, Estonia, France, Guatemala, Hungary, Israel, Italy, Japan, Korea, Republic of, Malaysia, Netherlands, Poland, Portugal, Puerto Rico, Romania, Spain, Taiwan, Turkey, Ukraine, United Kingdom, Denmark, ... and more
Alexion Pharmaceuticals, Inc.

Completed

Danicopan as Add-on Therapy to a C5 Inhibitor in Paroxysmal Nocturnal Hemoglobinuria (PNH) Participants Who Have Clinically Evident Extravascular Hemolysis (EVH)(ALPHA)

Paroxysmal Nocturnal Hemoglobinuria

France, Italy, Spain, United States, Taiwan, Thailand, Korea, Republic of, Japan, Malaysia, Brazil, Germany, Israel, Czechia, Netherlands, Greece, United Kingdom, Canada, Poland
Novartis Pharmaceuticals

Active, not recruiting

Study of Efficacy and Safety of Brolucizumab Versus Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy (CONDOR)

Proliferative Diabetic Retinopathy

China, India, Japan, Russian Federation, Turkey, Canada, United States, Australia, Korea, Republic of, Brazil, Philippines, Puerto Rico, Taiwan, Argentina, Chile, Mexico
AstraZeneca

Completed

Study of Durvalumab With Chemoradiotherapy for Women With Locally Advanced Cervical Cancer (CALLA) (CALLA)

Locally Advanced Cervical Cancer

United States, Taiwan, Korea, Republic of, Brazil, Hungary, India, Japan, Mexico, Peru, Philippines, Poland, Russian Federation, China, Chile, South Africa
Hoffmann-La Roche
Chugai Pharmaceutical

Active, not recruiting

A Phase III Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibitors. (COMMODORE 2)

Paroxysmal Nocturnal Hemoglobinuria

Spain, Korea, Republic of, France, Sweden, Thailand, Malaysia, China, Turkey, Netherlands, Japan, Australia, United Kingdom, Germany, South Africa, Brazil, Romania, Argentina, Poland, Greece, Hong Kong, Lithuania, Mexico, Philippines, Portuga... and more
Boehringer Ingelheim

Completed

A Study to Test the Effect of Different Doses of Avenciguat (BI 685509) on Kidney Function in People With Chronic Kidney Disease

Chronic Kidney Disease

Spain, Canada, Australia, United States, Japan, Malaysia, United Kingdom, China, Mexico, Denmark, Russian Federation, Germany, Portugal, Hong Kong, Poland, Argentina, New Zealand, Sweden
Eisai Inc.

Recruiting

A Study of E7386 in Combination With Other Anticancer Drug in Participants With Solid Tumor

Neoplasms | Carcinoma, Hepatocellular | Liver Neoplasms | Colorectal Neoplasms | Endometrial Neoplasms

United States, Taiwan, France, Japan, Korea, Republic of
Eli Lilly and Company

Active, not recruiting

A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer (EMBER)

Breast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Endometrial Cancer

United States, Spain, France, Belgium, Taiwan, Australia, Korea, Republic of, Japan
Chinook Therapeutics U.S., Inc.

Active, not recruiting

Atrasentan in Patients With IgA Nephropathy (ALIGN)

Immunoglobulin A Nephropathy | IgA Nephropathy

United States, Spain, Taiwan, Hong Kong, China, New Zealand, United Kingdom, Korea, Republic of, Canada, Australia, Germany, France, India, Japan, Argentina, Italy, Brazil, Colombia, Poland, Portugal
Reata, a wholly owned subsidiary of Biogen

Completed

A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Alport Syndrome - CARDINAL (CARDINAL)

Alport Syndrome

United States, United Kingdom, Japan, Australia, France, Germany, Puerto Rico, Spain
Bayer

Completed

Factor XI LICA to Reduce Events Such as Heart Attack and Stroke in Patients Whose Kidneys Are no Longer Able to Work as They Should and Require Treatment to Filter Wastes From the Blood: Focus is on the Safety of BAY2976217 and the Way the Body Absorbs, Distributes and Removes the Study Drug (RE-THINc ESRD)

End Stage Renal Disease Requiring Hemodialysis

Belgium, United States, Latvia, Taiwan, Germany, Japan, Spain, Canada, Bulgaria, Greece, Ukraine, Czechia, Hungary, Korea, Republic of, Russian Federation
Janssen Research & Development, LLC

Recruiting

A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG) (SunRISe-5)

Non-Muscle Invasive Bladder Neoplasms

Korea, Republic of, United States, Argentina, Belgium, Brazil, China, Poland, United Kingdom, Italy, Japan, Germany, Romania
Merck Sharp & Dohme LLC
GOG Foundation; European Network for Gynaecological Oncological Trial groups(ENGOT)

Recruiting

Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)

Endometrial Cancer

Poland, United States, Canada, Australia, Israel, Korea, Republic of, Spain, Chile, France, Puerto Rico, Greece, Netherlands, Norway, Singapore, Switzerland, Argentina, Austria, Belgium, Czechia, Denmark, Finland, Malaysia, Sweden, Italy and more
Eisai Inc.
Merck Sharp & Dohme LLC

Active, not recruiting

Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775])

Endometrial Neoplasms

France, Canada, United States, Spain, United Kingdom, Italy, Taiwan, Korea, Republic of, Colombia, Australia, New Zealand, Brazil, Turkey, Poland, Israel, Argentina, Germany, Ireland, Japan, Mexico, Russian Federation
Novartis Pharmaceuticals

Recruiting

Efficacy and Safety of Iptacopan (LNP023) in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor Therapy (APPELHUS)

Atypical Hemolytic Uremic Syndrome

China, Korea, Republic of, Austria, Taiwan, Greece, Czechia, United States, Japan, Brazil, United Kingdom, India, Slovakia, Slovenia
AstraZeneca
Parexel; George Clinical Pty Ltd

Terminated

A Study to Evaluate the Safety and Efficacy of AZD5718 in Participants With Proteinuric Chronic Kidney Disease

Chronic Kidney Disease

United States, Taiwan, Germany, Hungary, Malaysia, Japan, Israel, Poland, Brazil, Ukraine, Argentina
Janssen Research & Development, LLC

Recruiting

A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder (SunRISe-2)

Urinary Bladder Neoplasms

Taiwan, Korea, Republic of, Austria, Germany, China, United States, Greece, Italy, Argentina, Belgium, Brazil, Russian Federation, Spain, Canada, Czechia, France, Mexico, Japan, Poland, Portugal, Australia, Hungary, Turkey, India, Ukraine
Novartis Pharmaceuticals

Terminated

A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma

Melanoma | Head and Neck Cancer | Pancreatic Cancer | Urothelial Cancer | NSCLC, Non Small Cell Lung Cancer | RCC, Renal Cell Cancer | DLBCL, Diffused Large B Cell Lymphoma | MSS, Microsatellite Stable Colon Cancer | TNBC, Triple Negative Breast Cancer | mCRPC, Metastatic Castration Resistant Prostate...

Belgium, Italy, Taiwan, Germany, Spain, United States, Argentina, Australia, Austria, Czechia, France, Japan, Netherlands, Switzerland, Singapore
Hoffmann-La Roche

Recruiting

A Study to Evaluate the Efficacy and Safety of RO7434656 in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression (IMAGINATION)

Primary IgA Nephropathy

Korea, Republic of, Australia, Spain, United Kingdom, Taiwan, China, Japan, France, United States, Italy, Greece, Czechia, Singapore, Hong Kong, Argentina, Malaysia, Germany, Brazil, Poland, Canada
Novartis Pharmaceuticals

Terminated

Study of Safety, Efficacy and Tolerability of Secukinumab Versus Placebo, in Combination With SoC Therapy, in Patients With Active Lupus Nephritis (SELUNE)

Lupus Nephritis

China, Croatia, Czechia, Russian Federation, Turkey, Australia, Spain, Thailand, Argentina, United States, Denmark, Greece, Romania, Germany, Korea, Republic of, India, Brazil, Japan, Peru, Portugal, Italy, Taiwan, Vietnam, Norway, Colo... and more
Janssen Pharmaceutical K.K.

Completed

A Confirmatory Study of Fentanyl in Participants With Post-herpetic Neuralgia, Complex Regional Pain Syndrome or Postoperative Pain Syndrome

Postoperative Pain | Postherpetic Neuralgia | Complex Regional Pain Syndromes (CRPS)

Japan
Bristol-Myers Squibb
Eisai Inc.

Recruiting

A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Neoplasms, Ovarian

Australia, United States, Korea, Republic of, Chile, Belgium, Italy, Spain, Israel, Japan
AM-Pharma

Terminated

(Revival) Study to Investigate the Efficacy and Safety of Alkaline Phosphatase in Patients With Sepsis-Associated AKI

Acute Kidney Injury Due to Sepsis

Belgium, Spain, United States, Austria, Denmark, France, United Kingdom, Finland, New Zealand, Australia, Germany, Canada, Netherlands, Ireland, Japan
Hoffmann-La Roche

Recruiting

A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Bladder Cancer Who Are ctDNA Positive Following Cystectomy (IMvigor011)

Muscle-invasive Bladder Cancer

Belgium, Korea, Republic of, Japan, Brazil, China, United States, Singapore, France, United Kingdom, Canada, Greece, Italy, Spain, Turkey, Russian Federation, Ukraine, Israel, Czechia, Colombia, Hong Kong, Argentina, Germany, Ireland, Polan... and more
AstraZeneca
The Gynecologic Oncology Group (GOG) Foundation Inc; The European Network for...

Active, not recruiting

Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer (DUO-E)

Endometrial Neoplasms

United States, Belgium, Canada, Germany, Korea, Republic of, Brazil, Hungary, Japan, Poland, Russian Federation, China, Hong Kong, Spain, Israel, Australia, India, Singapore, Greece, Estonia, Lithuania, Mexico, Colombia
AstraZeneca

Active, not recruiting

Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC (NIAGARA)

Muscle Invasive Bladder Cancer

United States, Belgium, France, Germany, Italy, Spain, United Kingdom, Canada, Poland, Taiwan, Vietnam, Turkey, Korea, Republic of, Brazil, Czechia, Japan, Philippines, Israel, Chile, Australia, Netherlands, Russian Federation
AstraZeneca

Completed

Zibotentan and Dapagliflozin for the Treatment of CKD (ZENITH-CKD Trial) (ZENITH-CKD)

Chronic Kidney Disease

United States, Italy, Spain, Brazil, Malaysia, Australia, South Africa, Hungary, Georgia, Japan, Bulgaria, Poland, Ukraine, Denmark, Argentina, Slovakia, Canada, Croatia, Netherlands
Novo Nordisk A/S

Recruiting

A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo

Obesity | Type 2 Diabetes | Chronic Kidney Disease

Spain, United States, Poland, Thailand, India, France, Argentina, Brazil, Canada, Japan, Greece, Slovakia, Hungary
AstraZeneca
Gynecologic Oncology Group Foundation; European Network for Gynaecological...

Recruiting

Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical) (eVOLVECervical)

Locally Advanced Cervical Cancer

Spain, Korea, Republic of, Italy, Poland, Japan, Peru, China, Brazil, Taiwan, United States, Canada, India, Denmark, Mexico, Puerto Rico, Turkey, Norway
Bayer

Completed

Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease (FIDELIO-DKD)

Chronic Kidney Disease

Belgium, Finland, France, China, Hong Kong, Switzerland, United States, Turkey, Greece, New Zealand, Poland, South Africa, Spain, Korea, Republic of, Portugal, Taiwan, Japan, Russian Federation, Singapore, Australia, Netherlands, ... and more
Merck Sharp & Dohme LLC

Completed

Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826)

Cervical Cancer

Japan, United States, Argentina, Australia, Canada, Chile, Colombia, France, Germany, Israel, Italy, Korea, Republic of, Mexico, Peru, Russian Federation, Spain, Taiwan, Turkey, Ukraine
Novartis Pharmaceuticals

Active, not recruiting

Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients (APPLAUSE-IgAN)

IgA Nephropathy

United States, Taiwan, Czechia, Germany, Hungary, India, Turkey, Belgium, Netherlands, Singapore, Australia, Canada, Italy, Korea, Republic of, Spain, Thailand, Denmark, Slovenia, United Kingdom, Argentina, Brazil, Israel, Japan, France, Swed... and more
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Active, not recruiting

A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer

Urinary Bladder Neoplasms | Muscle-Invasive Bladder Cancer

Russian Federation, United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, Colombia, Finland, France, Germany, Greece, Israel, Italy, Japan, Korea, Republic of, Mexico, Netherlands, New Zealand, Norway, Portugal, Roman... and more
Astellas Pharma Inc
Seagen Inc.

Completed

A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer (EV-201)

Urologic Neoplasms | Urinary Bladder Neoplasms | Carcinoma, Transitional Cell | Ureteral Neoplasms | Urothelial Cancer | Urethral Neoplasms | Renal Pelvis Neoplasms

United States, Korea, Republic of, Spain, France, Germany, Italy, Japan, Netherlands
Merck Sharp & Dohme LLC
Eisai Inc.

Active, not recruiting

Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001) (LEAP-001)

Endometrial Neoplasms

Brazil, United States, Argentina, Australia, Austria, Belgium, Canada, China, Germany, Ireland, Israel, Italy, Japan, Korea, Republic of, Mexico, Poland, Russian Federation, Spain, Taiwan, Turkey, Ukraine, United Kingdom
AstraZeneca

Recruiting

Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin (VOLGA)

Muscle Invasive Bladder Cancer

Netherlands, United Kingdom, Korea, Republic of, Canada, Germany, Italy, Poland, Spain, Turkey, Vietnam, Argentina, Japan, France, Brazil, Taiwan, United States, Israel, Austria, Chile, Colombia, Greece, Hong Kong, Mexico, Portugal, Russian... and more
Merck Sharp & Dohme LLC

Active, not recruiting

Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866) (KEYNOTE-866)

Bladder Cancer

Canada, United States, Australia, Belgium, Denmark, France, Germany, Hungary, Ireland, Israel, Italy, Japan, Korea, Republic of, Mexico, Poland, Russian Federation, Spain, Sweden, Thailand, Turkey, Ukraine, United Kingdom
Janssen Research & Development, LLC

Recruiting

A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy (SunRISe-1)

Urinary Bladder Neoplasms

United States, Belgium, Korea, Republic of, Germany, Italy, France, Spain, Canada, United Kingdom, Greece, Japan, Australia, Netherlands, Portugal, Russian Federation, Ukraine
Hoffmann-La Roche
Chugai Pharmaceutical

Recruiting

A Study Evaluating The Safety, Pharmacokinetics, and Efficacy Of Crovalimab Versus Eculizumab In Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors (COMMODORE 1)

Paroxysmal Nocturnal Hemoglobinuria

Korea, Republic of, Spain, United States, Germany, Estonia, Japan, Colombia, Turkey, Brazil, France, Greece, Poland, Taiwan, Netherlands, Saudi Arabia, Italy, Australia, Sweden, Singapore, Portugal, Hungary, Belgium, Canada, Czechia, Hong... and more
Merck Sharp & Dohme LLC
Astellas Pharma Inc; Seagen Inc.

Active, not recruiting

Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304) (KEYNOTE-B15)

Bladder Cancer

Hungary, United States, China, Argentina, Australia, Bulgaria, Canada, Colombia, Croatia, Czechia, France, Germany, Greece, Israel, Italy, Japan, Korea, Republic of, Malaysia, Philippines, Poland, Portugal, Romania, Russian Federation, Singapo... and more
AstraZeneca

Recruiting

Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis (IRIS)

Lupus Nephritis

China, United States, Hungary, Germany, Italy, Belgium, India, Mexico, Vietnam, Argentina, Bulgaria, Colombia, Japan, Turkey, Taiwan, Thailand, France, Netherlands, Brazil, Malaysia, Peru, Poland, Russian Federation
Boehringer Ingelheim
Eli Lilly and Company; Medical Research Council Population Health Research...

Active, not recruiting

EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin)

Chronic Kidney Disease

United States, Canada, United Kingdom, China, Germany, Italy, Japan, Malaysia
Bristol-Myers Squibb

Terminated

A Study Comparing the Efficacy and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG) Versus BCG Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (CheckMate 7G8)

Urinary Bladder Neoplasms

United States, Netherlands, Italy, Argentina, Australia, Austria, Brazil, Canada, Chile, France, Germany, Greece, Israel, Japan, Russian Federation, Spain, Sweden
Merck Sharp & Dohme LLC
GOG Foundation; European Network of Gynaecological Oncological Trial Groups...

Active, not recruiting

Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)

Endometrial Neoplasms

Australia, United States, Germany, Israel, Korea, Republic of, Poland, Turkey, Belgium, Brazil, Canada, Chile, China, Czechia, Denmark, Finland, Hungary, Ireland, Italy, Japan, Netherlands, New Zealand, Norway, Russian Federation, Spain, Swed... and more
Hoffmann-La Roche
Chugai Pharmaceutical

Recruiting

A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS) (COMMUTE-a)

Atypical Hemolytic Uremic Syndrome

Canada, United States, Japan, France, Spain, Mexico, Peru, Brazil, New Zealand, Belgium, China, Germany, Hungary, Israel, Italy, Poland, South Africa, Turkey, India

Clinical Trials on Surgery-Complications in Japan

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Belarus

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations